Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic and Extraglycemic Goals in Type 2 Diabetes: A ClinicalImpact Curriculum

Get patient-specific guidance on GLP-1 RA options using this Interactive Decision Support Tool. Then, review commentaries, perspectives, and slides from a panel of experts.
Martin J. Abrahamson, MD, FACP
Anne Peters, MD
John J. Russell, MD

Downloadable Slidesets

Learn about the appropriate use of GLP-1 RAs to address elevated A1C, obesity, and CV risk, as well as strategies to improve tolerability and adherence.

John J. Russell, MD Released: December 23, 2019

Learn about the place of GLP-1 RAs in T2D; their impact on A1C, obesity, and CV risk; and strategies to improve tolerability and adherence.

Martin J. Abrahamson, MD, FACP Anne Peters, MD Released: January 17, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novo Nordisk

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?